Organogenesis

organogenesis.com · Canton, United States of America

Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes advanced wound care and surgical biologic products for hospitals, outpatient wound centers, and physician offices. Its portfolio includes cellular and acellular tissue-based products used to treat chronic and acute wounds, as well as products for surgical and sports medicine applications. The company generates revenue by selling these FDA-regulated biologic and medical device products through direct sales and distributor channels primarily in the United States and select international markets.

Revenue
$250M - $1B
Employees
201 - 1,000
Founded
1985
Headquarters
Canton, United States of America

Organogenesis customers on Arbolus

Total customers 14 14 current · 0 former
Reviews growth 9 new reviews since Apr 2026

Customers who reviewed Organogenesis

Seniority of Organogenesis customers

Most people who reviewed Organogenesis hold C-Suite roles (77%), followed by Manager (15%) and Director (8%).

  • C-Suite 77%
  • Manager 15%
  • Director 8%

Customers sample

Other Generalist Director NPS 10 Will renew
Other Generalist Manager NPS 3 Undecided
Other Generalist C-Suite NPS 7

Employer names and spend open in the full report, along with the other 11 customers.

What 14 Arbolus experts think of Organogenesis

Overall sentiment: Positive

NPS scores range from 3 to 10, with most responses at 7 or above, indicating generally positive feedback. Renewal intent is predominantly affirmative among high spenders and influencers, with a minority of users expressing uncertainty. 80% of experts have more than one year of adoption, reflecting strong stickiness. Key themes include positive clinical impact in complex cases, product selectivity based on evidence, and sensitivity to cost and budgetary constraints.

Everything 14 customers told us about Organogenesis.

Employer names, spend, renewal intent and every written answer behind the numbers on this page.

Sentiment

0 Net Promoter Score, from 14 scored reviews
  • Promoters 2
  • Passives 10
  • Detractors 2

Praised

  • Specialized Options for Difficult Cases
  • Effective in Complex and Chronic Wounds
  • Clinical Evidence-backed Solutions
  • Selective Expansion Through Data

Criticised

  • Competitive Value Offers
  • High Cost Sensitivity
  • AI as a Complement or Threat
  • Comparative Evidence Gaps

What Organogenesis customers say

Specialized Options for Difficult Cases

“I find their specialized range provides additional treatment options for wounds that haven't responded to standard care, reducing the need for repeat interventions.”

Other Generalist · Health Care · 10,000+ employees · EMEA

Effective in Complex and Chronic Wounds

“I use Organogenesis mainly for wounds slow to heal with standard treatments, especially diabetic foot ulcers, and have seen benefits in promoting wound closure.”

Other Generalist · Health Care · 10,000+ employees · EMEA

Clinical Evidence-backed Solutions

“I prioritize Organogenesis products when there’s strong clinical support and evidence that the product fits established wound care pathways.”

Other Generalist · Health Care · 10,000+ employees · EMEA

Renewal intent

Plan to renew 40%
  • Will renew 2
  • Undecided 3
  • Not renewing 0

Plan to renew, by seniority

  • C-Suite 50% 2 answers
  • Director 100% 1 answer
  • Manager 0% 2 answers
  • 9/10 Average score from customers who will renew
  • 5.3/10 Average score from undecided customers

Report

Sep 2026 14 + 0

For people who use Organogenesis

Do you use Organogenesis at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 14 customers of Organogenesis have already contributed

Takes a few minutes. Your identity stays anonymous.